India's First International News Journal

India's First International News Journal

Monday, September, 26, 2022

Press Release

Medtronic Commences PRAAN, India’s First-Ever Clinical Registry to Assess the Role of Brain Blood Clot Retrieving Devices in Stroke Patients
M

 

Mumbai, Maharashtra, India:
 India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc (NYSE:MDT) — a global leader in healthcare technology, today announced the launch of India’s first ever dedicated registry for the collection of real-world data associated with the use of revascularization devices in acute ischemic stroke (AIS) patients. The Prospective Registry for Assessment of Acute Ischemic Stroke Patients Treated with Neurothrombectomy Devices in India (PRAAN) is an industry-first endeavour to create a post-market registry to assess clinical outcomes associated with the use of Medtronic market-released revascularization devices in patients experiencing acute ischemic stroke. The duration of the registry will be approximately 28 months and up to 200 subjects will be enrolled in it. Devices that are used to restore blood flow in the brain by mechanically removing blood clots from occluded blood vessels are called neurothrombectomy (or mechanical thrombectomy) devices, which include stent retrievers and aspiration catheters.
 
In India, nearly 1.18 million patients are affected by stroke each year of which 68-80% of the strokes are ischemic (i.e., blood clot in the brain).1,2 Although current clinical practice guidelines recommend the use of neurothrombectomy for stroke management, patient utilization remains low in India. In India, while more than 2.7 lakhs patients are eligible for neurothrombectomy each year, fewer than 1500 (~0.5%) are treated with neurothrombectomy.3 Data emerging from prospective studies can provide information on patient characteristics, systems of care and the (short-term) clinical outcomes of neurothrombectomy on Indian patients. These data may provide valuable insights that will facilitate greater awareness of this therapy, improve care delivery systems and enable policy decisions to provide access to treatments.
 
Commenting on Medtronic’s disruptive efforts to sharpen clinical understanding of neurothrombectomy in AIS patients, Madan Krishnan, vice president and managing director, Medtronic India said, “Medtronic remains firmly committed to the practice of Evidence Based Medicine in the medical device industry in India. Facilitating patient access to life-saving therapies requires world-class clinical and economic outcomes evidence. The kickstart of PRAAN registry marks the beginning of one of many pioneering efforts undertaken by the company in stroke management. We hope to gain valuable insights from the emerging data from our prospective registry.”
 
Dr. Jeyaraj Pandian, vice president, World Stroke Organization and president, Indian Stroke Association, said, “Stroke is one of the leading causes of death and disability in India, and there exists a pressing need to deepen our understanding of stroke patients and prospective therapies and treatments. Medtronic’s PRAAN registry can play a critical first step in the creation of a comprehensive database for stroke patients in India, taking us closer to bringing beneficent therapy systems and policy interventions for their care.”
 
Dr. Vipul Gupta, neurointerventionist, Artemis Hospitals, Gurgaon, said, “While the treatment for stroke requires timely intervention before all else, the benefits of thrombectomy care in preventing morbidity is noteworthy. Stroke thrombectomy is minimally invasive, safe, and highly effective. Yet, its potential remains severely underutilized, and it is imperative to foster research and awareness around its benefits. I’m hopeful that the registry initiated by Medtronic will provide us robust data around effectiveness of mechanical thrombectomy in Indian patients.”
 
Subject enrolment for PRAAN is already underway, with 18 months of a scheduled enrolment window until February 2023. Publication of the reports of the registry is expected to happen in December 2023.
 
Mechanical thrombectomy with the use of stent retrievers has consistently shown improved neurological outcomes and reduced disability within 6 hours post stroke onset.4 Timely removal of blood clot via either neurothrombectomy devices, or clot-dissolving agent to restore the blood flow in brain is essential.5 Six landmark studies have reported reduced disability with the use of mechanical thrombectomy and clot-dissolving agent in patients with AIS.6-11 These outcomes resulted in the new 2015 American Heart Association (AHA/ASA) guidelines with an added recommendation for endovascular treatment with stent retrievers in subjects with large vessel occlusion (LVO).12

About Mechanical Thrombectomy

Based upon current clinical data and usage of these products, the risks associated with the Solitaire™ Revascularization Device and React™ Aspiration Catheter are outweighed by their individual and collective clinical benefits when used as intended in the target population.
 About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.
 Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
 
1 Banerjee TK, Das SK. Fifty years of stroke researches in India. Ann Indian Acad Neurol. 2016;19(1):1-8. doi:10.4103/0972-2327.168631
2 GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):439-458. doi:10.1016/S1474-4422(19)30034-1
3. Sundar K, Panwar A, Yagaval DR, Huded V, Sylaja PN. Mission Thrombectomy 2020 (MT2020)—India’s Biggest Healthcare Challenge Yet. J Stroke Med. 2020;3(2):62-71. doi:10.1177/2516608520984276
4. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Article. Stroke. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158
5. Zerna C, Thomalla G, Campbell BCV, Rha JH, Hill MD. Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke. Lancet. Oct 6 2018;392(10154):1247-1256. doi:10.1016/s0140-6736(18)31874-9
6. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. Jan 1 2015;372(1):11-20. doi:10.1056/NEJMoa1411587
7. Bracard S, Ducrocq X, Mas JL, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol. Oct 2016;15(11):1138-47. doi:10.1016/S1474-4422(16)30177-6
8. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. Mar 12 2015;372(11):1009-18. doi:10.1056/NEJMoa1414792
9. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. Mar 12 2015;372(11):1019-30. doi:10.1056/NEJMoa1414905             
10. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. Jun 11 2015;372(24):2296-306. doi:10.1056/NEJMoa1503780
11. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. Jun 11 2015;372(24):2285-95. doi:10.1056/NEJMoa1415061
12. Powers WJ, Derdeyn CP, Biller J, et al. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. Oct 2015;46(10):3020-35. doi:10.1161/STR.0000000000000074

Click here for Media Contact Details

Masooma Pathre (Public Relations), Medtronic plc, +91-9819744665

Ryan Weispfenning (Investor Relations), Medtronic plc, +1-763-505-4626

Submit your press release

Disclaimer: This Press Release has not been vetted or endorsed by The Eastern Herald's editorial staff.

The stories shaping the world

Partner Agency

Business Wire India
Business Wire India
The Business Wire India news distribution platform ensures that your news is disseminated instantaneously through key information systems.

Trending

You may consider